Pre-made Dalotuzumab benchmark antibody ( Whole mAb, anti-IGF1R therapeutic antibody, Anti-IGFR/CD221/IGFIR/JTK13 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-131

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-131 Category Tag

Product Details

Pre-Made Dalotuzumab biosimilar, Whole mAb, Anti-IGF1R Antibody: Anti-IGFR/CD221/IGFIR/JTK13 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Dalotuzumab is a humanized monoclonal antibody designed for the treatment of cancers.

Products Name (INN Index)

Pre-Made Dalotuzumab biosimilar, Whole mAb, Anti-IGF1R Antibody: Anti-IGFR/CD221/IGFIR/JTK13 therapeutic antibody

INN Name

Dalotuzumab

Target

IGF1R

Format

Whole mAb

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Discontinued

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2009

Companies

Pierre Fabre,Merck & Co

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Multiple myeloma,Neuroendocrine tumours,Non-small cell lung cancer,Solid tumours,Breast cancer,Colorectal cancer,Pancreatic cancer

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

IGF1R

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide